medigraphic.com
Colegio de Medicos y Cirujanos República de Costa Rica

2011, Number 599

<< Back Next >>

Rev Med Cos Cen 2011; 68 (599)

Avances en anticoagulación oral: dabigatran

Cordero AM

Language: Spanish
References: 10
Page: 411-413
PDF size: 244.79 Kb.


ABSTRACT

Thrombotic events and different pathologies require anticoagulation for months, years and even exceptionally for life. Warfarin has been the first choice drug for this, but its therapeutic index, interactions and different effect in every patient make difficult its use. This fact cause headache to physicians and patients because require frequent lab test and medical consult. Now days, companies have been working trying to find different molecules with the same effectiveness, greater security and a simpler use than Warfarin. So direct inhibitors of Trombine with its more important molecule Dabigatran generate a promising future for all mankind, but it is still under investigation.


REFERENCES

  1. Arguedas Quesada, A. Warfarina. Actualización Médica Periódica 2004, edición 35. Pág. 1-11.

  2. Conolly et al. Dabigatran versus Warfarin in Patients with Atrial Fibrillation n engl j med 361; 12 nejm.org September 17, 2009

  3. Ezecowitz, M et al. Dabigatran with or without aspirin compared with warfarin alone in patients with non valvular atrial fibrillation (PETRO study) Am J Cardiol 2007;100:1419 –1426

  4. Houston, D et al. Dabigatran versus Warfarin in patients with atrial fibrillation. n engl j med 361;27

  5. Houston, D et al. Dabigatran versus Warfarin in patients with atrial fibrillation. n engl j med 361;12

  6. Monreal Bosch, M et al. Avances en prevención y tratamiento de la enfermedad tromboembolica. Aplicaciones en la práctica Clínica. Medicine. 2009;10(46):3047-54

  7. Quesada, O. Novedades en coagulación, trombosis y Hemostasia. Nuevos anticoagulantes orales. Actualización Médica Periódica 2-2011, edición 117. Pág. 1-24.

  8. Schulman, S et al. Dabigatran versus warfarin in the treatment of acute venous tromboembolism. n engl j med 361;24

  9. Valerie L. Monitoring anticoagulation. Clin Lab Med 29 (2009)283-304

  10. Wallentin, L et al. Efficacy and safety of Dabigatran compared with warfarin at different levels of international normal-ized ratio control for stroke prevention in atrial fibrillation; an analysis of RE-LY trial. Lancet 2010; 376: 975–83.




2020     |     www.medigraphic.com